End-of-day quote
Korea S.E.
03:30:00 14/05/2024 am IST
|
5-day change
|
1st Jan Change
|
19,710
KRW
|
-0.05%
|
|
-0.66%
|
-16.66%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1,28,464
|
1,10,323
|
1,11,130
|
99,170
|
1,25,151
|
1,64,817
|
Enterprise Value (EV)
1 |
74,549
|
58,483
|
66,326
|
35,265
|
-1,74,506
|
-70,366
|
P/E ratio
|
43.6
x
|
16.9
x
|
39.4
x
|
-82.8
x
|
1.2
x
|
-7.9
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2.08
x
|
2.28
x
|
2.74
x
|
2.36
x
|
2.04
x
|
2.11
x
|
EV / Revenue
|
1.21
x
|
1.21
x
|
1.63
x
|
0.84
x
|
-2.85
x
|
-0.9
x
|
EV / EBITDA
|
14.1
x
|
32
x
|
59.7
x
|
27.6
x
|
-39.7
x
|
14.3
x
|
EV / FCF
|
4.65
x
|
6.88
x
|
-28.6
x
|
-7.82
x
|
-1.29
x
|
6.31
x
|
FCF Yield
|
21.5%
|
14.5%
|
-3.49%
|
-12.8%
|
-77.5%
|
15.9%
|
Price to Book
|
0.4
x
|
0.36
x
|
0.37
x
|
0.33
x
|
0.28
x
|
0.42
x
|
Nbr of stocks (in thousands)
|
6,719
|
6,719
|
6,719
|
6,719
|
7,414
|
6,969
|
Reference price
2 |
19,120
|
16,420
|
16,540
|
14,760
|
16,880
|
23,650
|
Announcement Date
|
01/03/19
|
29/02/20
|
01/03/21
|
01/03/22
|
01/03/23
|
29/02/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
61,653
|
48,412
|
40,601
|
42,090
|
61,248
|
78,053
|
EBITDA
1 |
5,272
|
1,828
|
1,111
|
1,276
|
4,391
|
-4,907
|
EBIT
1 |
2,258
|
-1,257
|
-1,948
|
-1,797
|
1,297
|
-7,993
|
Operating Margin
|
3.66%
|
-2.6%
|
-4.8%
|
-4.27%
|
2.12%
|
-10.24%
|
Earnings before Tax (EBT)
1 |
4,587
|
9,179
|
4,417
|
-1,523
|
1,37,973
|
-21,345
|
Net income
1 |
2,946
|
6,719
|
3,220
|
-1,368
|
1,05,241
|
-20,941
|
Net margin
|
4.78%
|
13.88%
|
7.93%
|
-3.25%
|
171.83%
|
-26.83%
|
EPS
2 |
438.4
|
971.7
|
419.9
|
-178.3
|
14,104
|
-2,994
|
Free Cash Flow
1 |
16,019
|
8,499
|
-2,317
|
-4,509
|
1,35,215
|
-11,160
|
FCF margin
|
25.98%
|
17.56%
|
-5.71%
|
-10.71%
|
220.77%
|
-14.3%
|
FCF Conversion (EBITDA)
|
303.87%
|
465%
|
-
|
-
|
3,079.15%
|
-
|
FCF Conversion (Net income)
|
543.85%
|
126.5%
|
-
|
-
|
128.48%
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
01/03/19
|
29/02/20
|
01/03/21
|
01/03/22
|
01/03/23
|
29/02/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
53,916
|
51,840
|
44,804
|
63,905
|
2,99,657
|
2,35,182
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
16,019
|
8,499
|
-2,317
|
-4,509
|
1,35,215
|
-11,160
|
ROE (net income / shareholders' equity)
|
0.91%
|
2.01%
|
0.93%
|
-0.39%
|
26.6%
|
-5.04%
|
ROA (Net income/ Total Assets)
|
0.41%
|
-0.22%
|
-0.33%
|
-0.3%
|
0.19%
|
-1.09%
|
Assets
1 |
7,24,964
|
-30,65,032
|
-9,79,994
|
4,52,069
|
5,62,18,584
|
19,24,007
|
Book Value Per Share
2 |
48,272
|
45,051
|
45,310
|
45,106
|
60,097
|
56,158
|
Cash Flow per Share
2 |
207.0
|
4,861
|
4,723
|
6,630
|
36,811
|
23,488
|
Capex
1 |
1,209
|
1,240
|
4,817
|
10,930
|
62,011
|
7,727
|
Capex / Sales
|
1.96%
|
2.56%
|
11.87%
|
25.97%
|
101.25%
|
9.9%
|
Announcement Date
|
01/03/19
|
29/02/20
|
01/03/21
|
01/03/22
|
01/03/23
|
29/02/24
|
|
1st Jan change
|
Capi.
|
---|
| -16.66% | 102M | | +21.28% | 43.92B | | +24.47% | 23.09B | | +19.22% | 15.35B | | +12.87% | 13.61B | | +44.67% | 12.02B | | -9.92% | 7B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +13.07% | 5.6B |
Generic Pharmaceuticals
|